دورية أكاديمية
Rationale for combined therapies in severe-to-critical COVID-19 patients
| العنوان: | Rationale for combined therapies in severe-to-critical COVID-19 patients |
|---|---|
| المؤلفون: | Gonzaga, Aitor, Andreu, Etelvina, Hernández-Blasco, Luis M., Meseguer, Rut, Al-Akioui-Sanz, Karima, Soria-Juan, Bárbara, Sanjuan-Gimenez, Jose Carlos, Ferreras, Cristina, Tejedor, Juan Ramón, López-Lluch, Guillermo, Goterris, Rosa, Maciá, Loreto, Sempere-Ortells, Jose M., Hmadcha, Abdelkrim, Borobia, Alberto, Vicario, Jose L., Bonora, Ana, Aguilar-Gallardo, Cristobal, Poveda, Jose L., Arbona, Cristina, Alenda, Cristina, Tarín, Fabian, Marco, Francisco M., Merino, Esperanza, Jaime, Francisco, Ferreres, José, Figueira, Juan Carlos, Cañada-Illana, Carlos, Querol, Sergio, Guerreiro, Manuel, Eguizabal, Cristina, Martín-Quirós, Alejandro, Robles-Marhuenda, Ángel, Pérez-Martínez, Antonio, Solano, Carlos, Soria, Bernat |
| المساهمون: | Instituto de Salud Carlos III, Generalitat Valenciana |
| بيانات النشر: | Frontiers Media |
| سنة النشر: | 2023 |
| المجموعة: | Digital.CSIC (Consejo Superior de Investigaciones Científicas / Spanish National Research Council) |
| مصطلحات موضوعية: | COVID-19, Cytokine storm, Immunomodulation, Mesenchymal stromal cells, SARS-CoV-2, Advanced therapies |
| الوصف: | An unprecedented global social and economic impact as well as a significant number of fatalities have been brought on by the coronavirus disease 2019 (COVID-19), produced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Acute SARS-CoV-2 infection can, in certain situations, cause immunological abnormalities, leading to an anomalous innate and adaptive immune response. While most patients only experience mild symptoms and recover without the need for mechanical ventilation, a substantial percentage of those who are affected develop severe respiratory illness, which can be fatal. The absence of effective therapies when disease progresses to a very severe condition coupled with the incomplete understanding of COVID-19’s pathogenesis triggers the need to develop innovative therapeutic approaches for patients at high risk of mortality. As a result, we investigate the potential contribution of promising combinatorial cell therapy to prevent death in critical patients. ; This research was funded by the financial support to BS from: Institute of Health Carlos III (Co-funded by Fondos FEDER), Project ICI21/00016 and Agencia Valenciana de Innovacion Projects AVI-GVA COVID-19-68 and GVA-COVI19/2021/047 and Project JDRF 2-SRA-2019-837. BS strongly appreciates the support of his family and friends. ; Peer reviewed |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | unknown |
| العلاقة: | Publisher's version; http://dx.doi.org/10.3389/fimmu.2023.1232472Test; Sí; e-issn: 1664-3224; Frontiers in Immunology 14: 1232472 (2023); http://hdl.handle.net/10261/341905Test |
| DOI: | 10.3389/fimmu.2023.1232472 |
| الإتاحة: | https://doi.org/10.3389/fimmu.2023.1232472Test http://hdl.handle.net/10261/341905Test |
| حقوق: | open |
| رقم الانضمام: | edsbas.676BC0D5 |
| قاعدة البيانات: | BASE |
| DOI: | 10.3389/fimmu.2023.1232472 |
|---|